-
公开(公告)号：KR101729348B1
公开(公告)日：2017-04-24
申请号：KR1020120053393
申请日：2012-05-21
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/09 , A23L1/30
Abstract: 본발명은면역반응의이상으로유발되는면역질환을예방또는치료하는데사용되는메트포민(metformin) 화합물의약학적용도에관한것으로서, 보다구체적으로는메트포민(metformin) 화합물을유효성분으로포함하는면역질환의예방또는치료용조성물에관한것이다. 본발명에따른메트포민(metformin) 화합물은염증성사이토카인을생성및 분비하는세포독성 Th17 세포로의분화를억제하는효과가우수하고, 비정상적으로활성화된면역세포의기능을억제하고염증반응을제어하는특성을갖는면역조절 T 세포(Treg)의활성을증진시키는효과가우수하며, 조절 T 세포(Treg)의 Th17 세포로의분화가변성(plasticity)을억제하는활성을통하여조절 T 세포(Treg)로서의기능을효과적으로유지및 강화시키는효과가우수하여, 각종면역반응의조절이상으로유발되는자가면역질환, 염증성질환및 이식거부질환과같은면역질환을예방또는치료할수 있는약학적조성물또는면역억제제로유용하게사용할수 있다.
Abstract translation: 本发明涉及施加uiyakhak也用于预防或治疗在预防含有作为活性成分的化合物或自身免疫性疾病引起的免疫反应的异常，更具体地说euroneun二甲双胍（二甲双胍）自身免疫性疾病二甲双胍（二甲双胍）化合物 治疗组合物。 根据本发明（二甲双胍）二甲双胍化合物特性抑制细胞毒性的Th17分化为产生和炎性细胞因子的分泌，细胞优良的效果，和抑制一个不同寻常的活性免疫细胞的功能，和控制炎症反应 （Treg），已知它通过抑制调节性T细胞（Treg）的Th17细胞的分化可塑性的活性发挥调节性T细胞（Treg）的功能， 有效保持和增强固体，免疫自诱导通过在多种免疫应答的疾病的控制，可以是用于自身免疫性疾病如炎性疾病和移植排斥病症由所述药物组合物或可以预防或治疗免疫抑制剂有用的效果 有。
-
公开(公告)号：KR101273747B1
公开(公告)日：2013-06-12
申请号：KR1020100088295
申请日：2010-09-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/015 , A61P35/00
Abstract: 본 발명은 STA-21을 유효성분으로 포함하는 암 또는 면역질환의 예방 및 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 STA-21을 화합물 또는 그의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 암 또는 면역질환의 예방 및 치료용 조성물, 면역억제용 조성물, STA-21을 이용한 미분화 T 세포의 Th17 세포로의 분화를 감소 또는 억제하는 방법 및 조절 T 세포를 활성화시키는 방법에 관한 것이다. 본 발명에 따른 STA-21 화합물은 염증성 사이토카인을 생성 및 분비하는 세포 독성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)를 활성화 시키는 효과가 우수하므로 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 및 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용될 수 있는 효과가 있다.
-
公开(公告)号：KR1020120118596A
公开(公告)日：2012-10-29
申请号：KR1020110036053
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/497 , A61K31/495 , A61K31/4164 , A61P37/00
CPC classification number: A61K31/496 , Y10S514/825
Abstract: PURPOSE: A composition for preventing and treating immunization diseases including nutlin-3a compound is provided to suppress the expression of IL-17 through overexpression of p53. CONSTITUTION: A composition for preventing and treating immunization diseases includes nutlin-3a compound. The nutlin-3a compound suppresses the IL-17 production. The IL-17 production suppression is completed by the overexpression of p53. The immunization disease is autoimmune disease, inflammation disease, transplantation rejection disease of cell, tissue or organ. The autoimmune disease or inflammation disease is rheumatoid arthritis, asthma], dermatitis, psoriasis, cystic fibrosis, multiple sclerosis, systemic lupus erythematosus, sjogren syndrome, hashimoto thyroiditis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, inflammatory Bowel dieseses, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary diseases(COPD), Graves disease, gastrointestinal allergies, conjunctivitis, and atherosclerosis. [Reference numerals] (AA) Producing amount of IL-17(pg/ml)
Abstract translation: 目的：提供一种预防和治疗包括nutlin-3a化合物在内的免疫疾病的组合物，以通过p53的过表达抑制IL-17的表达。 构成：用于预防和治疗免疫疾病的组合物包括nutlin-3a化合物。 Nutlin-3a化合物抑制IL-17的产生。 IL-17产生抑制由p53的过表达完成。 免疫疾病是自身免疫性疾病，炎症疾病，细胞，组织或器官的移植排斥疾病。 自身免疫疾病或炎症疾病是类风湿性关节炎，哮喘，皮炎，牛皮癣，囊性纤维化，多发性硬化，系统性红斑狼疮，干燥综合症，麻疹甲状腺炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎，肺纤维化， 炎性肠病，自身免疫性糖尿病，糖尿病性视网膜病变，鼻炎，缺血再灌注损伤，血管成形术后再狭窄，慢性阻塞性肺疾病（COPD），格雷夫斯病，胃肠道过敏，结膜炎和动脉粥样硬化。 （标号）（AA）IL-17的产生量（pg / ml）
-
公开(公告)号：KR1020120061025A
公开(公告)日：2012-06-12
申请号：KR1020110049894
申请日：2011-05-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/166 , A61K31/16 , A61K31/06 , A61P21/00
Abstract: PURPOSE: A composition containing AG490 compounds is provided to enhance regulatory T cell(Treg) activity and to prevent or treat immune diseases. CONSTITUTION: A composition for preventing or treating immune diseases contains AG490 compounds of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The immune diseases are autoimmune diseases, inflammatory diseases, and transplantation rejection. A method for reducing or suppressing differentiation of undifferentiated T cells in vitro into Th17 cells comprises a step of treating AG490 compounds or pharmaceutically acceptable salt thereof to the undifferentiated T cells.
Abstract translation: 目的：提供含有AG490化合物的组合物以增强调节性T细胞（Treg）活性并预防或治疗免疫疾病。 构成：用于预防或治疗免疫疾病的组合物含有化学式1的AG490化合物或其药学上可接受的盐作为活性成分。 免疫疾病是自身免疫性疾病，炎性疾病和移植排斥反应。 将体外未分化T细胞分化为Th17细胞的方法包括将AG490化合物或其药学上可接受的盐治疗至未分化T细胞的步骤。
-
25.发明授权
公开(公告)号：KR101724169B1
公开(公告)日：2017-04-06
申请号：KR1020120098140
申请日：2012-09-05
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/1709 , A61K38/1761 , C07K14/47 , G01N33/6872 , G01N33/6893 , G01N2333/4704 , G01N2500/04 , G01N2500/10 , G01N2800/044
Abstract: 본발명은 Grim19 단백질을유효성분으로포함하는비만또는지질관련대사성질환의예방또는치료용조성물에관한것으로, 특히면역반응의이상또는유전적, 대사적, 환경적복잡한요인의상호작용에의해유발되는대사성질환을예방또는치료할수 있는 Grim19 단백질을유효성분으로포함하는비만또는지질관련대사성질환의예방또는치료용조성물에관한것이다. 본발명에따른상기 Grim19 단백질의경우, 지방세포감소효과및 체내총 콜레스테롤함량감소효과가우수한것으로나타났으며뿐만아니라염증성사이토카인을생성및 분비하는세포독성 Th17 세포의분화를억제하는효과가우수하고, 비만과관련된염증환경을 Grim19가 STAT3를매개하여염증반응을조절하는효과가우수하다는사실을확인함으로써, 비만또는지질관련대사성질환을효과적으로치료할수 있는치료제및 기능성식품의제조에사용될수 있는효과가있다.
Abstract translation: 本发明由相关的肥胖或脂质造成的，更特别地，大于或遗传，代谢，环境和的一种组合物的免疫应答用于预防或治疗代谢疾病，包括GRIM19蛋白作为活性成分的复杂因素相互作用 以及用于预防或治疗肥胖症或与脂质相关的代谢疾病的组合物，其包含能够预防或治疗代谢疾病的Grim19蛋白作为活性成分。 对于根据本发明，脂肪细胞减少和总体内胆固醇降低的效果和显现出生被抑制的细胞毒性的Th17的生产和炎性细胞因子的分泌的分化，以及细胞是优异的优异效果的GRIM19蛋白 可与肥胖相关联GRIM19生产炎性环境中使用的通过介导STAT3的效果确认的事实，调节炎症反应优异的效果，肥胖或脂质相关的可以有效治疗代谢性疾病，药物和功能性食品 有。
-
Patent Agency Ranking
公开(公告)号：KR101426689B1
公开(公告)日：2014-08-08
申请号：KR1020110036053
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/497 , A61K31/495 , A61K31/4164 , A61P37/00
Abstract: 본 발명은 Nutlin-3a 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 유효성분인 Nutlin-3a 화합물은 p53 과발현을 통해 IL-17의 발현을 억제시킴으로써 관절염 동물 모델에서 관절염을 개선시키는 효과 있으므로, 이를 유효성분으로 포함하는 본 발명의 조성물은 면역질환 예방 또는 치료에서 유용하게 사용될 수 있다.
-
公开(公告)号：KR1020140038898A
公开(公告)日：2014-03-31
申请号：KR1020130111679
申请日：2013-09-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61P29/00 , A61P1/00
CPC classification number: A61K31/155 , A61K38/1793 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to a composition for preventing or treating inflammatory bowel diseases comprising metformin as an active ingredient. A metformin compound or a composite of the metformin and etanercept (product name: Enbrel) have an excellent effect in maintaining the thickness of small intestines and the length of large intestines in a state similar to a normal state, an excellent effect in controlling or reducing the activity of IL-17 and TNF-a, and an excellent effect in promoting or increasing the activity of IFNr, thereby able to be practically used as a pharmaceutical composition for preventing or treating autoimmune diseases including the treatment of inflammatory bowel diseases.
Abstract translation: 本发明涉及一种预防或治疗包含二甲双胍作为活性成分的炎症性肠病的组合物。 二甲双胍化合物或二甲双胍和依那西普（产品名：Enbrel）的复合物在保持小肠厚度和大肠的长度处于类似于正常状态的状态下具有优异的效果，控制或减少的优异效果 IL-17和TNF-α的活性，并且在促进或增加IFNr的活性方面具有优异的效果，从而能够实际上用作预防或治疗包括治疗炎症性肠病的自身免疫性疾病的药物组合物。
-
公开(公告)号：KR1020140036598A
公开(公告)日：2014-03-26
申请号：KR1020120102887
申请日：2012-09-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61P37/00
CPC classification number: A61K31/155
Abstract: The present invention relates to a composition for preventing or treating immune diseases by suppressing B cell activities which are induced by metformin and, more specifically, to a composition for preventing or treating immune diseases, which includes a metformin compound or pharmaceutically acceptable salts thereof. The composition suppresses or reduces activities of etiological B cells. According to the present invention, the composition for preventing or treating immune diseases can be used as an immune suppressor by suppressing or reducing the etiological B cells in various autoimmune diseases, suppressing or reducing activities of etiological Th17 cells, and promoting or increasing activities of regulatory T cells (Treg).
Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性，更具体地说，涉及包含二甲双胍化合物或其药学上可接受的盐的免疫疾病的预防或治疗组合物，用于预防或治疗免疫疾病的组合物。 该组合物抑制或减少病原B细胞的活性。 根据本发明，用于预防或治疗免疫疾病的组合物可以通过抑制或减少各种自身免疫疾病中的病原B细胞，抑制或减少病原Th17细胞的活性，以及促进或增加调节活性 T细胞（Treg）。
-
公开(公告)号：KR1020140031614A
公开(公告)日：2014-03-13
申请号：KR1020120098140
申请日：2012-09-05
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/1709 , A61K38/1761 , C07K14/47 , G01N33/6872 , G01N33/6893 , G01N2333/4704 , G01N2500/04 , G01N2500/10 , G01N2800/044
Abstract: The present invention relates to a composition for preventing or treating obesity or metabolic diseases which includes Grim19 protein as an active ingredient and, specifically, to a composition for preventing or treating obesity or metabolic diseases including Grim19 protein as an active ingredient which can prevent or treat metabolic diseases caused by immune response disorder or interactions of genetically, metabolically, and environmentally complex factors. The Grim 19 proteins according to the present invention, fat cell reduction effects and total in vivo cholesterol amount are enhanced, suppression of differentiation of cytotoxic Th17 cells which produce and secrete inflammatory cytokine is enhanced, and effects of controlling inflammatory environment related to obesity using STAT3 as a mediator by the Grim19 so that the Grim 19 proteins can be used for manufacturing medicines and functional foods which can effectively treat obesity or lipid related metabolic diseases.
Abstract translation: 本发明涉及用于预防或治疗肥胖或代谢疾病的组合物，其包括Grim19蛋白作为活性成分，具体地，涉及用于预防或治疗肥胖症或代谢疾病的组合物，包括Grim19蛋白作为活性成分，其可以预防或治疗 由免疫应答障碍引起的代谢疾病或遗传，代谢和环境复杂因素的相互作用。 根据本发明的Grim19蛋白质，脂肪细胞减少作用和总体内胆固醇含量增强，产生和分泌炎症细胞因子的细胞毒性Th17细胞分化的抑制被增强，并且使用STAT3来控制与肥胖有关的炎症环境的效果 作为Grim19的调解人，使Grim 19蛋白质可用于制造能够有效治疗肥胖或脂质相关代谢疾病的药物和功能性食品。
-
公开(公告)号：KR1020120118978A
公开(公告)日：2012-10-30
申请号：KR1020110036667
申请日：2011-04-20
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/428 , A61K38/17 , A61P19/02 , A61P17/00
CPC classification number: A61K38/1758 , Y10S514/885 , Y10S530/868
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.
Abstract translation: 目的：提供用于预防或治疗包括P53在内的免疫疾病的组合物，以抑制引起免疫疾病的炎性细胞因子IL-17。 构成：用于预防或治疗免疫疾病的组合物包括P53作为活性成分。 P53具有通过炎性细胞因子的形成抑制来预防或治疗免疫疾病的活性。 炎性细胞因子是IL-17。 该组合物还包括用于促进p53表达或促进蛋白质活性的物质。 用于预防或治疗的组合物包括编码P53的多核苷酸。 加密p53蛋白质的多核苷酸以连接到表达相同的载体的重组载体类型提供。 表达P53蛋白的表达载体是非病毒载体或病毒载体。
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.027 seconds)
